Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Alnylam Pharmaceuticals Inc
Gross Profit
Alnylam Pharmaceuticals Inc
Gross Profit Peer Comparison
Competitive Gross Profit Analysis
Latest Figures & CAGR of Competitors
Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
Gross Profit
$1.7B
|
CAGR 3-Years
52%
|
CAGR 5-Years
101%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Gross Profit
$36.1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Gross Profit
$20.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Gross Profit
$19.6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
3%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Gross Profit
$8.8B
|
CAGR 3-Years
16%
|
CAGR 5-Years
26%
|
CAGR 10-Years
26%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Gross Profit
$11.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
13%
|
CAGR 10-Years
18%
|
See Also
What is Alnylam Pharmaceuticals Inc's Gross Profit?
Gross Profit
1.7B
USD
Based on the financial report for Mar 31, 2024, Alnylam Pharmaceuticals Inc's Gross Profit amounts to 1.7B USD.
What is Alnylam Pharmaceuticals Inc's Gross Profit growth rate?
Gross Profit CAGR 5Y
101%
Over the last year, the Gross Profit growth was 76%. The average annual Gross Profit growth rates for Alnylam Pharmaceuticals Inc have been 52% over the past three years , 101% over the past five years .